Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Director, Senior Legal Counsel||
|Fort Worth, TX|
|Senior Scientist - Cell Engineering Group||
|San Francisco, CA|
|Associate Director, Compliance Business Partner I||
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
|Silver Spring, MD, MD|
|Counsel – Regulatory Affairs||
RAI Services Company
|Winston Salem, NC|